Using an S Corp election can help flippers and short-term rental owners reduce self-employment taxes.
IQALUIT, Nunavut — Nunavut is reporting two COVID-19 cases in Kinngait, Nunavut, but the territory's chief public health officer says they're not related to the ongoing outbreak in Iqaluit. Until now, Iqaluit was the only one of Nunavut's 25 communities with active cases of COVID-19. Dr. Michael Patterson confirmed the two cases in a news release tonight, bringing Nunavut's active case count to 30. Starting tomorrow, all travel to and from Kinngait, a community of about 1,400 on the southern tip of Baffin Island, is restricted. Kinngait will also see the same lock down measures as Iqaluit, with indoor public gatherings banned and schools shut. With the new cases reported in Kinngait, all communities in the Baffin region will face increased restrictions, with gatherings restricted to a household plus five people and schools moving to a blend of in-class and remote learning. Earlier in the day, the territory also confirmed six more cases in Iqaluit where an outbreak has shut down all schools, non-essential businesses and workplaces. Nunavut's chief public health officer said all those currently infected with COVID-19 in Iqaluit, a city of about 8,000, were adults mostly in their 20s and 30s. Patterson declared an outbreak in the capital on Friday, two days after Iqaluit's first case in the pandemic was reported. Anyone who left the city on or after April 7 was asked to isolate in his or her home community for 14 days. "Mandated isolation is also an important measure to reduce the risk of spreading the virus to other communities," Patterson said. He said that, as of Sunday, 130 contacts involving the Iqaluit cases had been identified. He also said cases will continue to rise for the next few days as contact tracing continues in Iqaluit. Between five and 10 per cent of high-risk contacts will usually test positive for COVID-19. But Patterson also said the number of high-risk contacts has already started to drop. "As we catch up to the train of transmission, we've already seen that ... drop over the last 24, 48 hours." Patterson said he didn't know if the 28 people infected in Iqaluit had been vaccinated, but added there is "no evidence of vaccine failure." The source of Iqaluit's first COVID-19 case is also still unknown. The first case was a Canadian North airline worker who had been in the territory for over two weeks before showing symptoms. It's possible the person contracted the virus in Iqaluit, Patterson said. Since that first case was reported April 14, there have been 263 COVID-19 tests in Iqaluit, 235 of which were negative. Iqaluit's lab can process about 200 COVID tests a day, but Patterson said it's only needing to run 70 to 80 tests right now. To date, 14,255 people in Nunavut have received one dose of the Moderna vaccine and 10,933 are fully vaccinated. The territory is home to about 40,000 people. Health Minister Lorne Kusugak urged Nunavut residents not to travel in or out of the territory unless it's needed. "Cases in many parts of the country are rising rapidly. The variants are a huge concern and question mark. Please don't take chances unless it is necessary," Kusugak said. Samples of the positive tests have been sent to a southern lab to test for variants of concern, but results won't be back until the end of the week. This report by The Canadian Press was first published April 19, 2021. --- This story was produced with the financial assistance of the Facebook and Canadian Press News Fellowship. Emma Tranter, The Canadian Press
The latest news on COVID-19 developments in Canada (all times eastern): 8:05 p.m. Yukon's chief medical officer of health confirmed a new COVID-19 case in the territory today. Dr. Brendan Hanley says the person is from rural Yukon and had travelled within the country. This brings the total number of cases in the territory to 77. Last week, the territory confirmed its first case of the P.1 variant, which is the strain first identified in Brazil. --- 5:55 p.m. Alberta is reporting 1,391 new cases of COVID-19 and three additional deaths due to the virus. The province says 1,160 cases of variants have also been identified in the last 24 hours. Variants currently make up almost 57 per cent of the province’s 18,424 active cases. There are 460 people in hospital due to COVID-19, and 104 are in intensive care. --- 3:35 p.m. Saskatchewan is reporting 243 new cases of COVID-19. The province says there have been no new deaths due to the virus. It says there are 200 people in hospital because of COVID-19, and 43 of them are in intensive care. --- 2:50 p.m. Dr. Allison Furey, wife of Newfoundland and Labrador Premier Andrew Furey, has stepped up to help Ontario battle its soaring COVID-19 case numbers. The premier told reporters today that his wife has been working on the front lines in a St. John’s COVID-19 assessment unit, and that she’s eager to help out in Ontario. Furey says he spoke with Ontario’s deputy health minister, Helen Angus, early this morning about how Newfoundland and Labrador could help the province meet its need for health-care workers. He told reporters today he expects officials to work out a plan for sending workers to Ontario within the next 24 hours. --- 2:15 p.m. Newfoundland and Labrador is reporting three new cases of COVID-19. Health officials say two new cases are linked to travel within Canada, and the other is a close contact of a previously identified infection. There are now 25 active reported cases of COVID-19 in the province. Public health says contact tracers are still working to chase down the source of one of those infections, which was announced last Thursday. --- 1:45 p.m. Nunavut's chief public health officer says all those currently infected with COVID-19 in Iqaluit are adults. Dr. Michael Patterson also says about three-quarters of them are in their 20s and 30s. Nunavut is reporting six new cases of COVID-19, all in Iqaluit, bringing the city's total to 28 cases. Patterson declared an outbreak in the city on April 16, after its first case was reported on April 14. The city of about 8,000 people, the only place in Nunavut with active cases, is under a strict lockdown with schools, non-essential businesses and government offices closed. --- 1:35 p.m. Manitoba is lowering the age eligibility for COVID-19 vaccines. Anyone 40 and over can now get the Oxford-AstraZeneca vaccine. The change follows similar moves by Ontario and Alberta on the weekend. Pfizer-BioNTech and Moderna doses are available for First Nations people in Manitoba aged 34 and up and for others aged 54 and up. The province reported 108 new COVID-19 cases and no new deaths today. --- 1:30 p.m. New Brunswick is reporting nine new cases of COVID-19 today. Health officials say the hard-hit Edmundston region has six new cases while the Moncton, Fredericton and Bathurst areas each have one new case. There are 158 active reported cases in the province and 21 patients are hospitalized with the disease, including eight in intensive care. New Brunswick has administered more than 200,000 doses of COVID-19 vaccine, with 27.5 per cent of the eligible population 16 and over having received at least one dose. --- 1:15 p.m. Nova Scotia is reporting 15 new cases of COVID-19 today and now has 63 active cases. Eight of the cases are in the Halifax area, six are in the eastern zone and one is in the western area of the province. Seven of the 15 cases are related to travel outside of Atlantic Canada, five are close contacts of previously reported cases and three are under investigation. As of Sunday, the province has administered 207,563 doses of COVID-19 vaccine with 32,496 people having received their required second dose. --- 12 p.m. Prince Edward Island is increasing travel restrictions in an effort to control the number of COVID-19 cases in the province. All non-resident travel to the Island from outside Atlantic Canada is on hold until at least May 17. The province is reporting three new cases of COVID-19 today — all involving people who arrived from outside the Atlantic region. Rotational workers and truck drivers who arrive in the province will need to isolate until they receive a negative COVID-19 test even if they are vaccinated. --- 11:30 a.m. NDP Leader Jagmeet Singh wants Prime Minister Justin Trudeau to consider invoking the federal Emergencies Act given the dire pandemic outlook in Ontario. In a letter to Trudeau, Singh says such a declaration could help ensure a more co-ordinated delivery of vaccines to those who need them most. Singh says it would also allow workers to prevent the spread of COVID-19 by taking paid sick days and time off to get vaccinated. The NDP leader says in Toronto, the wealthiest neighbourhoods have higher rates of vaccination than neighbourhoods where racialized and working-class people live — areas that have higher levels of COVID-19 positivity. --- 11:20 a.m. Manitobans 40 and older will soon be able to get the Oxford-AstraZeneca COVID-19 vaccine. A government source has told The Canadian Press the province is lowering the minimum age eligibility following similar moves by Ontario and Alberta. The source, who spoke on condition of anonymity, says an announcement is to be made today. Currently, the AstraZeneca vaccine in Manitoba is available to those 65 and older and to people between 55 and 64 with certain underlying medical conditions. --- 11:15 a.m. Alberta says residents born in 1981 or earlier will be eligible to get the Oxford-AstraZeneca COVID-19 vaccine. Premier Jason Kenney announced last night the province would lower the minimum age to receive the shot to 40 from 55. Bookings for the younger age cohort are to start tomorrow. Health Minister Tyler Shandro says lowering the age offers roughly 575,000 more Albertans access to a COVID-19 vaccine. --- 11 a.m. Quebec is reporting 1,092 new COVID-19 cases today and 15 more deaths attributed to the novel coronavirus, including two in the past 24 hours. Despite the notable drop in new, daily infections, health officials reported 686 hospitalizations, a rise of three, and 183 people in intensive care, a rise of eight. The province says it administered 40,433 COVID-19 vaccine doses Sunday; nearly 2.4 million Quebecers have received at least one dose. New restrictions between Ontario and Quebec went into effect today, limiting travel between the provinces in order to reduce the spread of virus variants. --- 10:50 a.m. Ontario is reporting 4,447 new cases of COVID-19 today and 19 more deaths attributed to the novel coronavirus. Health Minister Christine Elliott says there are 1,299 new cases in Toronto, 926 in Peel Region and 577 in York Region. The Health Department is reporting that 2,202 people are hospitalized with the disease, although the government notes that more than 10 per cent of hospitals did not submit data. There are 755 people in intensive care and 516 on ventilators. --- 10:45 a.m. Nunavut is reporting six new cases of COVID-19 today, all in Iqaluit. The capital city of about 8,000 people declared an outbreak April 17, two days after its first case was reported. There are now 28 active reported cases of COVID-19 in Nunavut, all in Iqaluit. Since the first case was reported last week, there have been 263 COVID-19 tests in Iqaluit, 235 of which have come back negative. --- 10:30 a.m. Canada hit the 10-million milestone this morning for total COVID-19 vaccines administered and is closing in fast on getting a first dose to one in four Canadians. With Ontario reporting almost 67,000 new vaccinations this morning, Canada surpassed the 10-million mark. About 9.1 million people have now received at least one dose, including about 915,000 who have received both required doses. This report by The Canadian Press was first published April 19, 2021. The Canadian Press
The high-rise could include up to 330 multifamily units in a 285 foot building, likely 26 to 28 stories.
What are NFTs, and should investors gamble on these assets? Here's the low-down on what investors need to know. The post Should Investors Buy Into the NFT Hype Today? appeared first on The Motley Fool Canada.
It's a race between the naturalistic "Nomadland" and the black-and-white "Mank." Constantly updated.
Nearly four in 10 private renters in England have lived in unhealthy or dangerous conditions, a survey by housing charity Shelter showed on Tuesday, with the coronavirus pandemic highlighting the "grim reality" of millions of tenants. Urgent action is needed to increase the rights of tenants, about half of whom said they had not asked for repairs for fear of eviction, said Shelter, reporting a spike in calls for help about poor conditions in privately rented homes due to COVID-19. "Yet this pandemic has exposed the grim reality that too many of the country's 11 million renters - including key workers, families and the elderly - wake up every day to mould, pests and dangerous hazards."
NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BELLUS Health Inc. (NASDAQ: BLU) between September 5, 2019 and July 5, 2020, inclusive (the “Class Period”), of the important May 17, 2021 lead plaintiff deadline. SO WHAT: If you purchased BELLUS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the BELLUS class action, go to http://www.rosenlegal.com/cases-register-2058.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose information that resulted in a scheme that: (1) deceived the investing public regarding BELLUS’s business, operations, drug products, drug product development, competition, and present and future business prospects; (2) facilitated the Company’s September 2019 public offering (“Offering”); (3) created artificial demand for the BELLUS common shares sold in the Offering; (4) enabled the Company to receive approximately $70 million in net proceeds from the sale of BELLUS common stock in the Offering; and (5) caused purchases of BELLUS publicly traded common stock at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the BELLUS class action, go to http://www.rosenlegal.com/cases-register-2058.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email email@example.com or firstname.lastname@example.org for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 email@example.com firstname.lastname@example.org email@example.com www.rosenlegal.com
New York, New York--(Newsfile Corp. - April 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MoneyGram International, Inc. (NASDAQ: MGI) between June 17, 2019 and February 22, 2021, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline.SO WHAT: If you purchased MoneyGram securities during the Class Period you may be entitled to compensation without payment of any out of pocket ...
The report offers the most up-to-date information on Rett Syndrome pipeline products being developed by notable companies such as Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and others.Los Angeles, USA , April 19, 2021 (GLOBE NEWSWIRE) -- Rett Syndrome Clinical Trials Review: An Updated Status Report on Emerging Drugs by DelveInsight The report offers the most up-to-date information on Rett Syndrome pipeline products being developed by notable companies such as Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and others. DelveInsight’s “Rett Syndrome Pipeline Insight” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Rett Syndrome pipeline landscapes. It comprises Rett Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Rett Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Rett Syndrome pipeline products. Some of the key takeaways of the Rett Syndrome Pipeline Report There is no cure for Rett syndrome. Around 8+ key companies are developing Rett Syndrome therapies. These key players are Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and others have their Rett Syndrome drug candidates in the different phases of clinical development. Trofinetide is a novel synthetic analogue of the amino‐terminal tripeptide of IGF-1 designed to treat the Rett Syndrome symptoms. Acadia has an exclusive license for developing and commercialising trofinetide in North America from Neuren Pharmaceuticals. The drug is in Phase III clinical evaluation for the treatment of Rett Syndrome.The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Orphan Drug designation to Neuren for trofinetide in Rett Syndrome. The FDA has also accorded Fast Track designation.In February 2020, GW Research initiated a phase III trial to investigate the long-term safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome. The trial is anticipated to be finished by June 2022.NLX-101 (previously known as F15599) is a Phase I drug intended to treat Rett's syndrome. It is a novel compound that activates serotonin 5-HT1A receptors with exceptional selectivity, having over 1000-fold higher affinity for this target over other receptors. Also, NLX-101 is a 'biased agonist' at 5-HT1A receptors, preferentially activating 5-HT1A receptors in those brain regions that control mood and cognition. The FDA and the EMA have awarded NLX-101 Orphan Drug Status. Get an overview of pipeline landscape @ Rett Syndrome Clinical Trials Analysis Rett Syndrome is a neurodevelopmental disorder, which affects girls almost exclusively. It is characterised by average early growth and development followed by a decrease of development, loss of purposeful use of the hands, distinctive hand movements, decreased brain and head growth, walking, seizures, and intellectual disability. There is no cure for the disease. Rett Syndrome treatment is symptomatic, focusing on managing symptoms and supportive, needing a multidisciplinary approach. Medication may be required for breathing irregularities and motor difficulties, and anticonvulsant drugs may be utilised to control seizures. Occupational therapy can benefit children develop skills required for performing self-directed activities, while physical therapy and hydrotherapy may prolong mobility. Rett Syndrome Emerging Drugs Trofinetide by Neuren Pharmaceuticals Trofinetide is a novel synthetic analogue of the amino‐terminal tripeptide of IGF-1 designed to treat the core symptoms of Rett Syndrome by reducing neuroinflammation and supporting synaptic function. Research and Development Phase III NCT04181723: ACADIA Pharmaceuticals, in November 2019, initiated a Phase III study titled “Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Trofinetide for the Treatment of Girls and Women with Rett Syndrome”. With an estimated 184 participants, the trial is currently in recruiting stage and expected to be completed by October 2021. Neuren's North American partner for trofinetide, ACADIA Pharmaceuticals, has commenced a Phase 3 trial ("Lavender") in Rett syndrome. Neuren previously conducted a Phase 2 double-blind placebo-controlled clinical trial in girls aged 5 to 15 years with Rett syndrome. This followed positive trends observed in Neuren's earlier Phase 2 trial in adolescents and adults aged 16 to 45 years. For further information, refer to the detailed report @ Rett Syndrome Pipeline Therapeutics Scope of Rett Syndrome Pipeline Drug Insight Coverage: Global Major Players: 8+ Key PlayersProminent Players: Anavex Life Sciences Corp., GW Research Ltd, Neuren Pharmaceuticals, Ultragenyx Pharmaceutical Inc., Edison Pharmaceuticals, Novartis, Neurolixis, Echo Pharmaceuticals, Relmada Therapeutics, and many others. Key Drugs Profiles: 8+ Products Phases: Rett Syndrome Therapies Late-stage (Phase III) Rett Syndrome Therapies Mid-stage (Phase II)Rett Syndrome Therapies Early-stage (Phase I) Rett Syndrome Pre-clinical stage and Discovery candidates Discontinued and Inactive candidates Mechanism of Action: Sigma-1 receptor agonistsCannabinoid receptor CB1, CB2 inverse agonistsCytokine inhibitors Molecule Types: Stem cell therapy Small molecule Gene therapy Route of Administration: InhalationIntravenous Oral Subcutaneous Product Types: MonotherapyCombinationMono/Combination Key Questions regarding Current Rett Syndrome Treatment Landscape and Emerging Therapies Answered in the Pipeline Report What are the current options for Rett Syndrome treatment?How many companies are developing therapies for the treatment of Rett Syndrome? How many are Rett Syndrome emerging therapies in the early-stage, mid-stage, and late development stages to treat Rett Syndrome?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Rett Syndrome market? Which are the dormant and discontinued products and the reasons for the same?What is the unmet need for current therapies for the treatment of Rett Syndrome? What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Rett Syndrome therapies? What are the critical designations that have been granted for the emerging therapies for Rett Syndrome? How many patents are granted and pending for the emerging therapies to treat Rett Syndrome? Table of Contents 1Rett Syndrome Introduction2Rett Syndrome Executive Summary3Rett Syndrome Overview4Rett Syndrome- Analytical Perspective In-depth Commercial Assessment5Rett Syndrome Pipeline Therapeutics6Rett Syndrome Late Stage Products (Registered)7Rett Syndrome Late Stage Products (Phase III)7.1Trofinetide: Neuren Pharmaceuticals7.2GWP42003-P: GW Research Ltd.8Rett Syndrome Mid Stage Products (Phase II/III)8.1ANAVEX2-73 oral liquid: Anavex Life Sciences Corp.9Rett Syndrome Mid Stage Products (Phase II)9.1Triheptanoin: Ultragenyx Pharmaceutical Inc.10Rett Syndrome Early Stage Products (Phase I)10.1NLX 101: Neurolixis11Rett Syndrome Pre-clinical and Discovery Stage Products12Rett Syndrome Therapeutic Assessment13Rett Syndrome Inactive Products14Company-University Collaborations (Licensing/Partnering) Analysis15Rett Syndrome Key Companies16Rett Syndrome Key Products17Rett Syndrome Unmet Needs18 Rett Syndrome Market Drivers and Barriers19Rett Syndrome Future Perspectives and Conclusion20Rett Syndrome Analyst Views21Appendix22About DelveInsight Get a customised pipeline report @ Rett Syndrome Drugs Pipeline Report Related Reports Rett Syndrome Market DelveInsight's Rett Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Rett Syndrome Epidemiology Forecast DelveInsight's Rett Syndrome - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Rett Syndrome in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Acute Coronary Syndrome Market DelveInsight's Acute Coronary Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Aicardi Goutieres Syndrome Market DelveInsight's Aicardi Goutieres Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Alagille Syndrome Market DelveInsight's Alagille Syndrome - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur firstname.lastname@example.org +1(919)321-6187 www.delveinsight.com
Calfrac Well Services Ltd. ("Calfrac" or the "Company") (TSX: CFW) announced today that its annual meeting of shareholders scheduled for Tuesday, May 4, 2021, at 3:30 p.m. (Calgary time) at the Calgary Petroleum Club will be changed to a virtual meeting to be held at the same time and on the same date.
Charles River Development announces Nomura Asset Management Co., Ltd. is expanding their use of the Charles River Investment Management Solution.
‘Remains to be seen how successful freeports will be’ in increasing trade and investment, MP says
Exxon Mobil on Monday floated a proposal for a public-private carbon storage project that would collect planet-warming carbon dioxide emissions from U.S. petrochemical plants and bury them in reservoirs under the Gulf of Mexico. The plan would require "$100 billion or more" from companies and government agencies to store 50 million metric tons of CO2 by 2030 with capacity potentially doubling by 2040, Joe Blommaert, president of Exxon's Low Carbon Solutions business said in an interview. Blommaert outlined the plan in a blog post on Monday, about two months after the largest U.S. oil producer formed a Low Carbon Solutions business unit to profit from selling carbon-reduction technology and services.
New York, New York--(Newsfile Corp. - April 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Infinity Q Diversified Alpha Fund Institutional Class ("Infinity Q") (NASDAQ: IQDNX) between December 21, 2018 and February 22, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District ...
The judge in the murder trial of ex-Minneapolis Police Officer Derek Chauvin said Rep. Maxine Waters' "disrespectful" remarks could lead to an appeal.
MIAMI (AP) The Houston Rockets say that guard Sterling Brown was assaulted by unknown individuals after the team arrived in Miami late Sunday night, suffering cuts to his face. Brown was not playing Monday against the Heat, though the team said that was because of a recent knee injury that has kept him out for a total of five games and not the altercation. ''Last night, Sterling Brown was the victim of an assault,'' the Rockets announced in a statement issued Monday evening.
PALM BEACH, Fla. — Demolition began Monday on a South Florida mansion that once belonged to disgraced financier Jeffrey Epstein. Developer Todd Michael Glaser oversaw the crews that began tearing down the infamous Palm Beach mansion, the Palm Beach Post reported. He previously said it would be personally satisfying to knock down and build a new one. Glaser bought the waterfront home last month for $18.5 million. Epstein, 66, killed himself in a Manhattan federal jail in August 2019 while he awaited trial on sex trafficking charges that alleged he abused women and girls under the age 18 at his Florida estate and his Manhattan mansion in the early 2000s. Epstein’s ex-girlfriend, Ghislaine Maxwell, remains jailed on sex-trafficking charges. She has pleaded not guilty, and a trial is set for July. The 59-year-old British socialite is accused of recruiting three girls, one as young as 14, in the 1990s for Epstein to sexually abuse during massage sessions at his New York and Florida homes. Prosecutors later added another sex trafficking charge for a fourth girl, who investigators said was groomed and abused in the early 2000s. The Associated Press
Two new cases of COVID-10 have been confirmed in Kinngait, Nunavut. The cases were announced by Dr. Michael Patterson, Nunavut's chief public health officer in a news release Monday. The cases are not linked to the outbreak in Iqaluit, it says. The territory now has 30 active cases of COVID-19, 28 of which are in Iqaluit. Contact tracing in the community has been started and Patterson says both individuals are isolating at home and doing well. "To contain any potential spread within the community, it's crucial that residents of Kinngait do their part and follow the updated public health measures," Patterson said. "Please be vigilant in staying home." New measures Effective 12:01 a.m. Tuesday, all travel to and from Kinngait is restricted, except for cargo and emergency travel. That includes all travel by land. All non-essential travel continues to be highly discouraged. Within Kinngait, all non-essential services and government offices must close. All indoor public gatherings are banned, and are limited to household members plus five people, for emergency purposes only. Outdoor gatherings are limited to five people. Schools are moving to remote instruction only, and daycares must close. In all other Qikiqtaaluk communities, the release says, indoor gatherings are restricted to a household's members plus a maximum of five, from one other household. Indoor gatherings in halls, conference spaces, government offices, Inuit organizations and hamlets are limited to 25 people or 50 per cent of the rated capacity, whichever is less. Outdoor gatherings will be limited to 25 people. Schools there will move to Stage 3, meaning blended online and in-person learning, and daycares can remain open. Masks will be mandatory in all public places in all Qikiqtaaluk communities and in Rankin Inlet. All other public health measures in Rankin Inlet will stay the same. Anyone who has travelled from Iqaluit after April 7 must isolate immediately. Premier Joe Savikataaq said that step is "critical." "As we continue with contact tracing, we cannot take chances or unnecessary risks," said Savikataaq. "If you are in a public space, you must wear a mask and maintain strong physical distance. Stay home as much as possible and ensure only one member of the household goes to the store or for essential services," he said. "We must all do our part to slow the spread of COVID-19." Anyone who thinks they've been exposed to COVID-19 is told to call the COVID-hotline at 1-888-975-8601 between 10 a.m. and 6 p.m. ET, or notify their community health centre right away, and immediately isolate at home for 14 days. People should not go to the health centre in person, the release says. The territory is set to provide an update in a news conference on Tuesday at 1 p.m. ET.
Follow latest updates from the Hennepin County Courthouse
Police are also responding to fewer crimes in person and releasing more suspects on bail, report says